According to a study using data from BIOBADADERM, a multicenter, prospective cohort study comparing the risk of infection during the use of biological drugs (from the anti-TNF group and ustekinumab) to classic drugs used in psoriasis, it was significantly increased for TNF antagonists [40]. The gene discussed is TNF; the disease is psoriasis.